AI Article Synopsis
- * Research on mice reveals that the main cause of tumor-associated anemia is reduced red blood cell (RBC) survival, not just changes in RBC production.
- * Exercise training can improve metabolic profiles and reduce inflammation, leading to better RBC survival and decreased fatigue in cancer-bearing mice, suggesting a promising approach for enhancing quality of life in cancer patients.
Article Abstract
A considerable number of patients with cancer suffer from anemia, which has detrimental effects on quality of life and survival. The mechanisms underlying tumor-associated anemia are multifactorial and poorly understood. Therefore, we aimed at systematically assessing the patho-etiology of tumor-associated anemia in mice. We demonstrate that reduced red blood cell (RBC) survival rather than altered erythropoiesis is driving the development of anemia. The tumor-induced inflammatory and metabolic remodeling affect RBC integrity and augment splenic phagocyte activity promoting erythrophagocytosis. Exercise training normalizes these tumor-associated abnormal metabolic profiles and inflammation and thereby ameliorates anemia, in part, by promoting RBC survival. Fatigue was prevented in exercising tumor-bearing mice. Thus, exercise has the unique potential to substantially modulate metabolism and inflammation and thereby counteracts pathological remodeling of these parameters by the tumor microenvironment. Translation of this finding to patients with cancer could have a major impact on quality of life and potentially survival.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442918 | PMC |
| http://dx.doi.org/10.1126/sciadv.abi4852 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lorlatinib overcomes alectinib-induced hemolytic anemia in an ALK fusion positive non-small-cell lung cancer patient with severe tumor-associated liver failure: A case report.
Thorac Cancer
December 2024
Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
Hemolytic anemia is a rare and unique complication of alectinib, not observed with other anaplastic lymphoma kinase (ALK) inhibitors. Here, we present a case of an ALK fusion-positive non-small-cell lung cancer (NSCLC) patient who developed liver failure due to diffuse liver metastasis at initial diagnosis. Treatment was initiated with low-dose alectinib, but the patient developed severe hemolytic anemia.
View Article and Find Full Text PDFPediatric patients with von Hippel-Lindau and hemangioblastomas treated successfully with belzutifan.
Pediatr Blood Cancer
January 2025
Division of Pediatric Hematology/Oncology, UCLA, Los Angeles, California, USA.
Article Synopsis
- * Five pediatric patients with VHL-associated hemangioblastomas were treated with belzutifan, leading to improvements in tumor size and vision for those with retinal lesions, and benefits in neurologic symptoms for patients with intracranial tumors.
- * The treatment resulted in minor side effects, such as grade 1-2 anemia in four patients, and suggests belzutifan could be a promising therapy for young patients with these tumors.
A hypothesis on treatment strategy of severe multicentric Castleman disease with continuous renal replacement therapy.
J Cell Mol Med
September 2024
Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Castleman disease (CD) is a rare lymphoproliferative disorder, with non-specific clinical manifestations, often delayed diagnosis and treatment, which pose a significant challenge in the present times. Patients diagnosed with this disease have poor prognosis due to the limited treatment options. Multicentric CD occurs at multiple lymph node stations and is associated with a proinflammatory response that leads to the development of the so-called 'B symptoms'.
View Article and Find Full Text PDFPhase Ib/II Study of Lacnotuzumab in Combination with Spartalizumab in Patients with Advanced Malignancies.
J Immunother Precis Oncol
May 2024
Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Introduction: Blocking the colony-stimulating factor 1 (CSF-1) signal on tumor-associated macrophages can lead to an upregulation of checkpoint molecules, such as programmed cell death ligand 1 (PD-L1), thus causing resistance to this blockade. Combining spartalizumab (PDR001), a high-affinity, ligand-blocking, humanized anti-PD-1 immunoglobulin G4 antibody, with lacnotuzumab (MCS110), a high-affinity, humanized monoclonal antibody directed against human CSF-1 can potentially overcome this resistance.
Methods: This was a multicenter, phase Ib/II trial using a combination of spartalizumab with lacnotuzumab in patients with advanced cancers, including anti-PD-1/PD-L1 treatment-resistant melanoma, and anti-PD-1/PD-L1 treatment-naïve triple-negative breast cancer, pancreatic cancer, and endometrial cancer (ClinicalTrials.
Kasabach-Merritt Syndrome: a case study of successful treatment with vincristine and propranolol.
J Pak Med Assoc
December 2023
Interactive Research and Development (IRD), Global, Karachi, Pakistan.
Article Synopsis
- Kasabach-Merritt syndrome is a rare, serious condition that usually appears in infants and involves a growing vascular tumor, leading to low platelet counts and other blood-related issues.
- There are currently no established treatment guidelines, but a case report highlighted successful treatment in a four-month-old girl using a combination of propranolol and vincristine, which improved her condition.
- Early diagnosis and careful monitoring are key to managing the syndrome effectively, and documenting individual cases is crucial for understanding treatment outcomes since large studies are difficult to conduct.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!